DGIdb - FENOFIBRATE Drug Record

FENOFIBRATE chembl:CHEMBL672 Approved

Alternate Names:

FENOGLIDE
NSC-281319
FENOFIBRATE
LIPANTIL MICRO 200
LIPANTIL MICRO 67
TRICOR
TRIGLIDE
LIPOFEN
ANTARA
LIPANTIL MICRO 267
LIPIDIL
LIPANTIL
SUPRALIP 160
FENOGAL
TRICOR (TN)
TRICOR®
FENOFIBRATO
ABT-335
ISOPROPYL 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPIONATE
SUPRALIP®
2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPANOIC ACID 1-METHYLETHYL ESTER
FENOFIBRATUM
FINOFIBRATE
LIPANTIL (TN)
PROCETOFEN
FNF
ISOPROPYL (4'-(P-CHLOROBENZOYL)-2-PHENOXY-2-METHYL)PROPIONATE
LIPANTIL®
rxcui:221100
rxcui:8703
chemidplus:49562-28-9
pubchem.compound:3339
chembl:CHEMBL672
drugbank:01039

Drug Info:

FDA Approval	not approved
Drug Indications	anticholesterolaemic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidyslipidaemic agent
Drug Class	antilipemic agents
Year of Approval	1993
Drug Categories	lipid modifying agents
Drug Categories	isobutyrates
Drug Categories	benzophenones
Drug Categories	agents causing muscle toxicity
Drug Categories	bsep/abcb11 substrates
Drug Categories	cytochrome p-450 cyp2a6 inhibitors
Drug Categories	cytochrome p-450 cyp2a6 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	fribic acid derivatives
Drug Categories	hypolipidemic agents indicated for hyperlipidemia
Drug Categories	p-glycoprotein inhibitors
Drug Categories	peroxisome proliferator receptor alpha agonist
Drug Categories	peroxisome proliferator-activated receptor alpha agonists
Drug Categories	ugt1a9 substrates

(6 More Sources)

Publications:

Chaput et al., 2000, Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight., Biochem. Biophys. Res. Commun.
Casas et al., 2000, New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting., FEBS Lett.
Guerre-Millo et al., 2000, Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity., J. Biol. Chem.
Dana et al., 2001, Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat., Metab. Clin. Exp.
Clavey et al., 1999, Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells., Cell. Physiol. Biochem.
Bouly et al., 2001, Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate., J. Biol. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Foucher C et al., 2004, Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes., Pharmacogenetics
Blann et al., 2001, Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate., Am. J. Cardiol.
Chien KL et al., 2009, Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment., Pharmacogenomics
Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
Brisson D et al., 2002, Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients., Pharmacogenetics
Brouillette C et al., 2004, Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate., J Hum Genet
Hiuge et al., 2007, Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level., Arterioscler. Thromb. Vasc. Biol.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
Aslibekyan S et al., 2012, Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate., PLoS One
Watts et al., 2003, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome., Diabetes
Lai CQ et al., 2007, Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study., Arterioscler Thromb Vasc Biol
Liu Y et al., 2009, Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study., Pharmacogenet Genomics
Perez-Martinez P et al., 2009, Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states., Am J Clin Nutr
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Potaczek DP et al., 2006, Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients., Blood Coagul Fibrinolysis
Wang et al., 2003, Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles., Atherosclerosis
Sebestjen et al., 2004, Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors., Thromb. Haemost.
Lebrasseur et al., 2007, Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension., Hypertension
Duhaney et al., 2007, Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload., Hypertension
Creusot N et al., 2010, Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples., Anal Bioanal Chem

FENOFIBRATE APOA5

Interaction Score: 1.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17431185 19057464 19056598

Sources:
PharmGKB
FENOFIBRATE MMP25

Interaction Score: 1.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17606858 17353509

Sources:
DrugBank
FENOFIBRATE FABP1

Interaction Score: 1.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15249972

Sources:
PharmGKB
FENOFIBRATE ADIPOQ

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17194889

Sources:
NCI
FENOFIBRATE APOA1

Interaction Score: 0.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19207029 23119086

Sources:
PharmGKB
FENOFIBRATE SCARB1

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FENOFIBRATE CRP

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FENOFIBRATE TFPI

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15543343

Sources:
NCI
FENOFIBRATE CD40LG

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14612213

Sources:
NCI
FENOFIBRATE CFL1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16680159

Sources:
DTC
FENOFIBRATE PPARA

Interaction Score: 0.3

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist

Direct Interaction yes

Trial Name ABT-335, choline fenofibrate,TriLipix

PMIDs:
10799317 11018525 10828060 11474486 10494028 11342537 11752352 15608561

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
FENOFIBRATE APOB

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12606523

Sources:
NCI PharmGKB
FENOFIBRATE ABCA1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FENOFIBRATE APOE

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12042669

Sources:
PharmGKB
FENOFIBRATE LPL

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19207029

Sources:
PharmGKB
FENOFIBRATE IL6

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16607077

Sources:
PharmGKB
FENOFIBRATE HLA-A

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FENOFIBRATE SLCO1B1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16316932

Sources:
NCI PharmGKB
FENOFIBRATE JUN

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16680159

Sources:
DTC
FENOFIBRATE VEGFA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11356390

Sources:
NCI
FENOFIBRATE CDK1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16680159

Sources:
DTC
FENOFIBRATE CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
FENOFIBRATE NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

PMIDs:
20024649

Sources:
DrugBank
FENOFIBRATE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16316932

Sources:
NCI
FENOFIBRATE TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16680159

Sources:
DTC
FENOFIBRATE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FENOFIBRATE KCNH2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FENOFIBRATE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FENOFIBRATE CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FENOFIBRATE CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FENOFIBRATE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB01039

Version: 5.1.7

Alternate Names:

FENOFIBRATE DrugBank Drug Name

49562-28-9 CAS Number

Aa-feno-micro Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories acids, acyclic

Publications:

Lebrasseur et al., 2007, Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension., Hypertension

Duhaney et al., 2007, Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload., Hypertension

Chaput et al., 2000, Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight., Biochem. Biophys. Res. Commun.

TEND: FENOFIBRATE
- Version: 01-August-2011
Alternate Names:

FENOFIBRATE Primary Drug Name

Drug Info:

Year of Approval 1993

Drug Class antilipemic agents

Publications:
TdgClinicalTrial: FENOFIBRATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidyslipidaemic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: FENOFIBRATE

Version: 14-September-2017

Alternate Names:

C29047 NCI drug code

Drug Info:

Publications:

Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica

Wang et al., 2003, Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles., Atherosclerosis

Sebestjen et al., 2004, Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors., Thromb. Haemost.

DTC: FENOFIBRATE

Version: 02-September-2020

Alternate Names:

CHEMBL672 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

PharmGKB: fenofibrate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Brisson D et al., 2002, Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients., Pharmacogenetics

Lai CQ et al., 2007, Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study., Arterioscler Thromb Vasc Biol

Liu Y et al., 2009, Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study., Pharmacogenet Genomics

TTD: Fenofibrate
- Version: 2020.06.01
Alternate Names:

D07XGR TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103761
- Version: 29-September-2020
Alternate Names:

FENOFIBRATE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL672
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL672
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Peroxisome proliferator-activated receptor alpha agonist
Direct Interaction	yes
Trial Name	ABT-335, choline fenofibrate,TriLipix

FENOFIBRATE	DrugBank Drug Name
49562-28-9	CAS Number
Aa-feno-micro	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	acids, acyclic

FENOFIBRATE Drug Record

FENOFIBRATE chembl:CHEMBL672 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17431185 19057464 19056598

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17606858 17353509

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15249972

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17194889

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19207029 23119086

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15543343

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14612213

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16680159

Sources: DTC

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist Direct Interaction yes Trial Name ABT-335, choline fenofibrate,TriLipix

PMIDs: 10799317 11018525 10828060 11474486 10494028 11342537 11752352 15608561

Sources: TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12606523

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12042669

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19207029

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16607077

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16316932

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16680159

Interaction Types & Directionality:

n/a

PMIDs:
17431185 19057464 19056598

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17606858 17353509

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15249972

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17194889

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19207029 23119086

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15543343

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14612213

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16680159

Sources:
DTC

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist

Direct Interaction yes

Trial Name ABT-335, choline fenofibrate,TriLipix

PMIDs:
10799317 11018525 10828060 11474486 10494028 11342537 11752352 15608561

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
12606523

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12042669

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19207029

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16607077

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16316932

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16680159

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11356390

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16680159

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

partial agonist (activating)

PMIDs:
20024649

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
16316932

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16680159

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a